MEG3 and central nervous system cancer: Consistent with its tumor-suppressor role, the reduction of MEG3 expression has been observed in NFPA (Gejman et al., 2008; Cheunsuchon et al., 2011) as well as other types of tumors such as hepatocellular carcinoma (Braconi et al., 2011), non-small-cell lung cancer (Lu et al., 2013), glioma (Wang et al., 2012) and meningioma (Zhang et al., 2010).